Genetic Association with Response to Intravitreal Ranibizumab in Patients with Neovascular AMD
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
PURPOSE: Neovascular age-related macular degeneration (AMD) resulting in decreased central vision severely impairs affected individuals. Current standard treatment is an intravitreal anti-VEGF therapy (ranibizumab), but responses to treatment show large variability. Genetic factors that influence AMD and that affect the outcome of ranibizumab treatment were sought within a sample of Swiss patients. METHODS: Changes in visual acuity (VA) after initiation of anti-VEGF treatment were observed during 12 months, and percentiles of VA were calculated. Genotypes of polymorphisms in known AMD susceptibility loci (CFH, CFB, HTRA1, AMRS2, and VEGFA) as well as not yet reported AMD-associated genes (KDR, LRP5, and FZD4) were determined, and their frequencies were compared. RESULTS: Of the 309 eyes included in the study, 243 completed VA assessment. On average, 3.9 ±2.6 ranibizumab injections were administered. Based on the change in visual acuity, two responder groups were established: 63 eyes were assigned to the poor responders (≤25th percentile) and 63 eyes to the good responders (≥75th percentile). Individuals with genotype CC of p.Y402H in CFH had a decreased chance of positive treatment outcome compared with those with the CT and TT genotypes (P = 0.005 and P = 0.006). In this study, the genotype combination of AG at CFH with CT at FZD4 (SNP rs10898563) promised an increased chance of positive treatment outcome (P = 0.004). Furthermore, the association with the known genetic susceptibility loci CFH, HTRA1, and AMRS2 were confirmed, and a risk-conferring polymorphism in one new locus, LRP5, was identified. CONCLUSIONS: Genetic predisposition may account for the variability in response to anti-VEGF treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Results from studies evaluating the ARMS2 A69S and HTRA1 promoter polymorphisms are also conflicting with regard to treatment response and no definitive conclusions can be drawn.9–11”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [11]
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Bootstrap Methods and Their Application
Loughin, T. M., Davison, A. C., & Hinkley, D. V. (1999) · Journal of the American Statistical Association · doi:10.2307/2669707 · Cited by 5,418
Models for Longitudinal Data: A Generalized Estimating Equation Approach
Zeger, S. L., Liang, K.-Y., & Albert, P. S. (1988) · Biometrics · doi:10.2307/2531734 · Cited by 4,505 · cited 1×
“Resampling was performed separately in patients with one or with two treated eyes and iterated 5000 times.(50,51)”
MethodComplement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122 · cited 1×
“One of the most important seems to be the production of vascular endothelial growth factor (VEGF).(1,2) Intravitreal injection of the anti-vascular endothelial growth factor (anti-VEGF) compounds, ranibizumab (Lucentis; Novartis, Basel, Switzerland; and Genentech Inc.”
BackgroundComplement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Cited by
Items 101–120 of 120
Sigalingging, T., Perdamaian, A. B. I., Romdhoniyyah, D. F., Prayogo, M. E., Wardhana, F. S., Widayanti, T. W., Sasongko, M. B., Agni, A. N., Oka, C., & Supanji, S. (2022) · Medical Hypothesis Discovery & Innovation in Ophthalmology · doi:10.51329/mehdiophthal1448 · Cited by 3
“Several studies support the hypothesis that polymorphisms in CFH can cause nAMD [11-15].”
BackgroundResultParadigm of Susceptibility Genes in AMD and PCV
Riaz, M., & Baird, P. N. (2017) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-4-431-56511-6_14 · Cited by 2
Noh, D., Ryu, G., Lee, J., & Sagong, M. (2018) · Ophthalmologica · doi:10.1159/000486248 · Cited by 2
Kubicka‐Trząska, A., Karska‐Basta, I., Dziedzina, S., Sanak, M., & Romanowska‐Dixon, B. (2019) · Klinika Oczna · doi:10.5114/ko.2019.84560 · Cited by 2
“Obecnie wiadomo, że zarówno patogeneza AMD i jej przebieg kliniczny, jak i odpowiedź na leczenie u chorych na AMD mogą być modyfikowane jednocześnie przez kilka polimorfizmów genowych, których efekty mogą na siebie wzajemnie oddziaływać (17, 19, 20).”
BackgroundPharmacogenomics of Drugs in Ocular Therapeutics
Velpandian, T., & Kumaramanickavel, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-25498-2_4 · Cited by 1
Eisenbarth, W., Feucht, N., Enders, C., Maier, M. M., Lohmann, C. P., & MacKeben, M. (2015) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2014.08.004 · Cited by 1
Pharmacogenomics in Ophthalmology
Schwartz, S. G., Higashide, T., & Brantley, M. A. (2013) · Springer eBooks · doi:10.1007/978-81-322-1184-6_32 · Cited by 1
Sun, D. K. (2015) · UA Campus Repository (The University of Arizona)
Fuzzard, D. R. W., Guymer, R. H., & Finger, R. P. (2016) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-319-24097-8_3
Ryu, G., Noh, D., Lee, J., & Sagong, M. (2017) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2017.58.8.937
Wiggs, J. L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382227-7.00091-4
Freeman, E. E., & Gower, E. W. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-384978-6.00099-6
Genomics in Choroidal Neovascularization
Yamashiro, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-2213-0_6
Japiassú, R. M., Cialdini, A. P., Hilgert, C. R., & Bach, B. (2025) · Springer eBooks · doi:10.1007/978-3-031-29358-0_90-1
Pappas, C. M., Zouache, M. A., Matthews, S., Faust, C. D., Hageman, J. L., Williams, B. L., Richards, B. T., & Hageman, G. S. (2021) · Figshare · doi:10.6084/m9.figshare.16681651
Genetic markers of the effectiveness of anti-VEGF therapy in age-related macular degeneration
Bakunina, N. A., Николаевна, Т. С., Matyukhin, V. P., Anderzhanova, A., & Frolov, M. A. (2026) · Pharmacogenetics and Pharmacogenomics · doi:10.37489/2588-0527-0011
Japiassú, R. M., Cialdini, A. P., Hilgert, C. R., & Bach, B. (2026) · Springer eBooks · doi:10.1007/978-3-032-23052-2_90
Ceran, T. H., Beyatli, S., & Doğan, M. (2026) · BMC Ophthalmology · doi:10.1186/s12886-026-05491-4
“Finally, genetic and pharmacogenomic factors that may affect responsiveness to anti-VEGF therapy were not assessed [14].”
Metadata
- Authors
- Kloeckener-Gruissem, B., Barthelmes, D., Labs, S., Schindler, C., Kurz-Levin, M., Michels, S., Fleischhauer, J., Berger, W., Sutter, F., & Menghini, M.
- Affiliations
- From the Institute of Medical Molecular Genetics, University of Zurich, Schwerzenbach, Switzerland; the 2Department of Biology, ETHZ (Eidgenössische Technische Hochschule Zürich), Zurich, Switzerland;
- The University of Sydney (AU)
- University of Zurich (CH)
- Swiss Tropical and Public Health Institute (CH)
- University Hospital Zurich (CH)
- Triemli Hospital (CH)
- Corresponding author
- Barthelmes, Daniel
- Labs, Stephan
- Schindler, Christian
- Kurz-Levin, Malaika
- Michels, Stephan
- Fleischhauer, Johannes
- Berger, Wolfgang
- Sutter, Florian
- Menghini, Moreno
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2011-06-30
- Volume
- 52
- Issue
- 7
- Pages
- 4694
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2018291910
- Cited by
- 120
- References
- 57
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 2 · 2022: 5 · 2021: 4 · 2020: 3 · 2019: 7 · 2018: 9 · 2017: 8 · 2016: 7 · 2015: 14 · 2014: 16 · 2013: 21 · 2012: 18
- FWCI
- 17.10
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- neovascular age-related macular degeneration, ranibizumab, anti-VEGF therapy, treatment response variability, genetic susceptibility, complement factor H, CFH Y402H polymorphism, FZD4, LRP5, HTRA1, VEGF-A, KDR, visual acuity, genetic association
- MeSH terms
- Ranibizumab, High-Temperature Requirement A Serine Peptidase 1, Aged, Aged, 80 and over, Antibodies, Monoclonal, DNA, Dose-Response Relationship, Drug, Female, Fluorescein Angiography, Follow-Up Studies, Fundus Oculi, Genotype, Humans, Macular Degeneration, Male, Polymorphism, Genetic, Complement Factor B, Proteins, Serine Endopeptidases, Time Factors, Visual Acuity, Retinal Neovascularization, Polymerase Chain Reaction, Complement Factor H, Genetic Predisposition to Disease, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.